In one paragraphArticle in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
70 authors.
Pierre TeiraDepartment of Pediatrics, Department of Microbiology, Immunology and Infectious Diseases, Centre de Recherche Azrieli du CHU Sainte-Justine, University of Montreal, Montreal, Canada.ORCID https://orcid.org/0000-0002-6358-3771 Alfred P GillioPediatric Stem Cell and Cellular Therapy Division, Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health Hackensack University Medical Center, Hackensack, NJ, USA.ORCID https://orcid.org/0000-0001-8391-3101 Alan P KnutsenPediatric Allergy and Immunology, St. Louis University, St. Louis, MO, USA.
Theodore B MoorePediatric Blood and Marrow Transplant Program, Division of Pediatric Hematology/Oncology in the Department of Pediatrics, University of California, Los Angeles, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0002-7909-610X Donald B KohnPediatric Blood and Marrow Transplant Program, Division of Pediatric Hematology/Oncology in the Department of Pediatrics, University of California, Los Angeles, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0003-1840-6087 Luigi D NotarangeloLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0000-0002-8335-0262 Linda M GriffithDivision of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA.ORCID https://orcid.org/0009-0008-7368-3275 Elie HaddadDepartment of Pediatrics, Department of Microbiology, Immunology and Infectious Diseases, Centre de Recherche Azrieli du CHU Sainte-Justine, University of Montreal, Montreal, Canada.ORCID https://orcid.org/0000-0003-2446-6879 Funding
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MPB vs. BMU01HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2001 to 2010
$63.3MTraining of Clinical Investigators in Primary Immune DeficienciesU54AI082973 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PUCK, JENNIFER M. · 2009 to 2023
$23.3MData Management and Coordinating Center (DMCC)U54NS064808 · NINDS · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2009 to 2013
$16.5MPrimary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunityR24AI184316 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Christopher Craig Dvorak, Elie Haddad · 2024 to 2026
$5.3MClinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosageU01AI184132 · NIAID · NATIONAL MARROW DONOR PROGRAM · PI JEFFERY J AULETTA, Michael A Pulsipher · 2024 to 2026
$3.2MPrimary Immune Deficiency Treatment Consortium Annual Scientific MeetingR13AI094943 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PUCK, JENNIFER M. · 2011 to 2025
$239kNCI NIH HHS U24 CA076518NHLBI NIH HHS U01 HL069294NIAID NIH HHS R13 AI094943NIAID NIH HHS R24 AI184316NIAID NIH HHS U01 AI184132NIAID NIH HHS U54 AI082973NINDS NIH HHS U54 NS064808
6 · The paper itselfAbstract
Black race and Hispanic ethnicity are associated with higher mortality in severe combined immunodeficiency (SCID) following hematopoietic cell transplantation (HCT), though mechanisms remain unclear. We evaluated 796 children with SCID who received nonsibling HCT between 1982 and 2020 using data from the Primary Immune Deficiency Treatment Consortium. Overall survival for Black (aHR 2.47, 95%CI 1.64, 3.71) and Asian/Pacific Islander patients (aHR 1.82, 95%CI 1.00, 3.30) was significantly lower compared with non-Hispanic White patients, while Hispanic patients had lower event-free survival (aHR 1.83, 95%CI 1.27, 2.63) compared with non-Hispanic White patients. Even after adjusting for age and infection, Black patients with SCID had more than twofold hazard of death compared with non-Hispanic White patients. NBS was associated with earlier diagnosis, reduced infection at HCT, and elimination of survival disparities between Black and non-Hispanic White patients. These findings suggest that universal, system-level interventions such as NBS can mitigate disparities in outcomes for children with SCID.
Identifiers
PMID42416786
PMCPMC13340543
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390